EQS-News Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study
Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir
The relevant NeuroRx press release can be found here:
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.
RELIEF THERAPEUTICS Holding Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de